Key takeaways
- Six peptides—BPC-157, TB-500, MOTS-c, Semax, KPV, and Epitalon—can now be legally compounded by pharmacies, though the FDA opposed this move.
- Access requires a prescription, legitimate pharmaceutical sourcing, and quality testing, but this regulatory pathway is not FDA approval.
- Clinical evidence supporting these peptides for anti-aging or tissue repair remains limited, and experts warn against confusing access with safety.
- Expect higher prices due to compliance costs, and verify that your peptide comes from a legitimate compounding pharmacy.
In a move that has divided the medical and regulatory world, Health and Human Services secretary Robert F. Kennedy Jr. announced a new policy allowing six previously restricted peptides to be compounded by licensed pharmacies. The decision bypasses the Food and Drug Administration, which opposed the move. These six peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—are not FDA-approved and have not been added to the 503A Bulks List. Yet under the new “interim enforcement discretion policy,” the HHS says it will not enforce against pharmacies that compound these peptides, provided they follow specific regulations. For consumers interested in peptides for longevity, tissue repair, or anti-aging benefits, this represents a significant shift in legal access.
Six Peptides Now Available Through Compounding Pharmacies
What Changed at the Regulatory Level
In July, the Pharmacy Compounding Advisory Committee (PCAC) voted to loosen restrictions on these six peptides and move them toward the 503A Bulks List. That vote was advisory only. The FDA did not accept it. Instead, Kennedy’s HHS took a different path, announcing the interim enforcement discretion policy.
According to the Associated Press, FDA staff opposed the decision, and scientific staff had minimal input on it. This marks an unusual override of the FDA’s traditional regulatory authority. Each of the six peptides is restricted to specific delivery methods. Semax, for example, is limited to intranasal use. Users pursue these compounds for potential benefits related to muscle recovery, immune function, cognitive performance, or anti-aging, though clinical evidence remains limited.
How the Regulations Work
What Pharmacies Must Do
Compounding pharmacies can prepare these peptides only if they meet strict conditions. Raw ingredients must come from FDA-registered manufacturers that follow good manufacturing practices. Each batch requires a certificate of analysis documenting identity, purity, endotoxins, and absence of contaminants like heavy metals. Each compounded product can contain only one peptide, and the delivery method must match what the policy permits. Pharmacies must report any serious adverse events to the FDA and label products clearly as compounded drugs not for resale.
What Consumers Must Do
Unlike over-the-counter supplements, these peptides require a prescription from a licensed physician. This marks a move away from the gray market where peptides have been sold as “research-use-only” compounds despite their actual use by consumers. Now, consumers must consult a doctor, obtain a prescription, and fill it at a pharmacy that complies with the new rules.
Dustin Robinson, a regulatory lawyer specializing in emerging health sectors, explains the intent: to “move that demand into a channel with a pharmacist, a prescription, and a paper trail.”
Why the FDA Opposed This Decision
The Approval Gap
None of these six peptides have undergone the FDA’s approval process, which requires rigorous clinical testing on human populations. In 2025, Australian actor Richard Norton’s death was linked to excess use of a peptide obtained through a doctor’s prescription. While that particular peptide was not one of the six covered by the new policy, the case illustrates how peptide use can carry real risks when safety data is incomplete.
The Clinical Data Problem
Peptides marketed for collagen production, tissue repair, or longevity represent a frontier with very limited human clinical data. Dr. Ava Shamban, a board-certified dermatologist who has served as an investigator in FDA trials, states directly: “Access should never be confused with scientific or clinical validation.”
According to Allure, the lack of adequate human clinical data leaves critical questions unanswered about proper dosages, long-term safety, potential drug interactions, and whether peptides consistently deliver their promised benefits. Some have shown anecdotal benefits in tens of thousands of patients after decades of use under doctor supervision. Others are “not even remotely close to the timing, usage, or testing levels that would allow them to be considered safe without the full rigor of FDA approval,” Dr. Shamban says. For injectable compounds, concerns about purity, sterility, consistency, and immune reactions are especially acute. Biological plausibility—the idea that a mechanism of action makes scientific sense—does not equal proof of clinical benefit.
Access Versus Approval: Understanding the Difference
What the Policy Actually Is
The new policy creates a specific regulatory pathway without changing the peptides’ legal status. The HHS framed it as advancing “patient choice and freedom while appropriately protecting patient safety.” Legal experts caution against viewing this as FDA approval or endorsement.
David J. Holt, a healthcare attorney, describes it as “a highly specific safety valve meant to rescue patients from a dangerous black market by bringing oversight and structure to something already happening.” He emphasizes: “This is not a green light.”
What FDA Approval Actually Requires
To gain FDA approval, a drug must demonstrate not only efficacy but must “justify a safety population,” according to Dr. Steve Kates, vice president of regulatory affairs at Dicerna Pharmaceuticals. This typically requires two well-controlled clinical trials. The weight-loss drug Ozempic was tested on thousands of people before approval, generating massive amounts of safety data. These six peptides have no comparable body of evidence.
The new policy does establish one important floor: compounded peptides must meet strict quality standards, undergo testing, and be sourced from legitimate manufacturers. It attempts to cut off the overseas supply chain and gray market where most peptides have been sourced. But it does not establish that these peptides are safe or that they work.
What Changes for Prices and Market Access
Expect Costs to Rise
The new compliance requirements will increase peptide costs significantly. Pharmacies must source from FDA-registered manufacturers and conduct required testing. Demand will spike as peptides become more legally accessible, straining supply. Dustin Robinson notes supply chains may be “tight” at first as compounding infrastructure adjusts to meet demand.
The Gray Market Problem Persists
Jay Campbell, co-founder of the American Peptide Association, expects prices to “climb substantially.” This means consumers currently buying on the gray market may continue to do so rather than pay higher prices through legitimate channels. Additionally, “stacks” of combined peptides—popular among peptide users—are not covered under the new policy, leaving another avenue for gray-market commerce open.
Telehealth will likely become the primary entry point for consumers seeking legal prescriptions, creating both an opportunity for regulated access and a risk of inadequate medical oversight if providers lack peptide expertise.
Before You Ask Your Doctor for These Peptides
Safety Precautions
If you pursue one of these peptides through a compounding pharmacy, check that the label reads “This is a compounded drug product. Not for resale.” If it does not, it falls outside the HHS’s protective framework. Ask the pharmacy where the raw ingredient was manufactured; a legitimate pharmacy will have a clear answer. Review any documentation about reporting side effects, and report any adverse reactions so the FDA can compile real-world evidence.
Red Flags to Avoid
Clinics marketing these peptides as “FDA approved” are misleading customers. They are not FDA-approved and have not been added to the 503A Bulks List, regardless of marketing claims. Dr. Amanda Kahn, a board-certified internist, emphasizes that not all peptides are equal; some are well-researched, while others remain experimental. She encourages patients to start with a specific health goal rather than chasing peptides purely for anti-aging or enhancement.
The fact that a peptide has been used for years in clinical settings does not exempt it from formal FDA evaluation. The scientific standard that protects patients should not be weakened by conflating access with evidence.
Source: Allure
Frequently Asked Questions
Are these six peptides FDA-approved?
No. The new HHS policy allows compounding pharmacies to prepare them legally, but FDA approval is a separate process requiring clinical trials and demonstration of safety and efficacy. None of the six peptides have completed that process. According to Dr. Shamban, a dermatologist investigator in FDA trials, access should never be confused with scientific validation.
What do I need to do to get one of these peptides?
You need a prescription from a licensed physician. The peptide must be compounded by a pharmacy that sources raw ingredients from FDA-registered manufacturers and obtains a certificate of analysis documenting purity and absence of contaminants. The pharmacy must label it as a compounded drug not for resale. Over-the-counter purchase is not allowed.
Will these peptides become less expensive?
No, costs are expected to rise. Compounding pharmacies must now source from FDA-registered manufacturers, conduct quality testing, and meet regulatory requirements—all of which increase costs. According to Jay Campbell of the American Peptide Association, demand will spike while supply is tight, putting upward pressure on prices.
